Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
Open Access
- 1 September 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 94 (3) , 1252-1262
- https://doi.org/10.1172/jci117443
Abstract
Genetic and biochemical studies were carried out in 96 relatives of six independently ascertained probands with familial dysbetalipoproteinemia (FD) carrying the APOE*2 (Lys146-->Gln) allele. Compared to noncarriers, the 40 heterozygous APOE*2 (Lys146-->Gln) allele carriers exhibited markedly increased mean levels of cholesterol and triglyceride in the very low density lipoproteins (VLDL) (1.89 +/- 0.37 vs 0.30 +/- 0.27 and 1.86 +/- 0.37 vs 0.68 +/- 0.27 mmol/liter, respectively) and plasma apolipoprotein (apo) E levels (28.1 +/- 1.6 vs 4.6 +/- 1.1 mg/dl), which is characteristic for FD. By means of a pedigree-based maximum likelihood method we calculated that carrier-status accounted for 57% and 71%, respectively, of the total variance of the ratio (VLDL + IDL)-cholesterol/plasma triglyceride and plasma apoE levels. APOE*2 (Lys146-->Gln) and APOE*3-Leiden allele carriers were found to differ significantly in: (a) plasma apoE levels, (b) in the amounts of triglycerides in the VLDL and VLDL + IDL fraction, and (c) in the amount of cholesterol in the VLDL and VLDL + IDL fraction relative to the amount of triglyceride in these fractions. In the APOE*2 (Lys146-->Gln) allele carriers the VLDL and VLDL + IDL fraction is relatively rich in triglycerides as compared with that in APOE*3-Leiden carriers. We hypothesize that these two rare mutations of apoE both lead to dominantly inherited forms of FD along different underlying metabolic defects.Keywords
This publication has 43 references indexed in Scilit:
- Functionally inactive apolipoprotein E3 in a type III hyperlipoproteinaemic patientEuropean Journal of Clinical Investigation, 1984
- The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.Journal of Biological Chemistry, 1983
- The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.Journal of Biological Chemistry, 1983
- Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.Journal of Clinical Investigation, 1983
- Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3.Journal of Clinical Investigation, 1983
- Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.Proceedings of the National Academy of Sciences, 1982
- Human apolipoprotein E. The complete amino acid sequence.Journal of Biological Chemistry, 1982
- Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.Journal of Biological Chemistry, 1981
- HUMAN APOLIPOPROTEIN-E ISOPROTEIN SUBCLASSES ARE GENETICALLY-DETERMINED1981
- Familial hyperlipoproteinemia type III: Deficiency of a specific apolipoprotein (APO E‐III) in the very‐low‐density lipoproteinsFEBS Letters, 1975